5 Stocks to Watch: Week of 1/19/2026

This week’s list of stocks to watch features a variety of sectors and price points, but there’s one common thread: They all rank exceptionally well in our 115-factor Zen Ratings system. Here’s what we’ve got:

• Enhabit (EHAB) benefits from increased hospice demand 
• Eli Lilly & Co (LLY) continues to lead the GLP-1 market
• SiriusPoint (SPNT) expands its services
• Taboola (TBLA) makes strides in the AI sphere
• Ibex (IBEX) is an under-the-radar gem poised to explode

P.S. Missed last week’s picks? Get 'em here.

A note from our sponsors...

1- SiriusPoint (NYSE: SPNT)

SiriusPoint Limited is a global insurer and reinsurer that recently expanded its services following the acquisition of Assist America, positioning itself for enhanced growth. Analysts forecast nearly 50% potential upside in the coming year. 

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $19.92 — get current quote

Max 1-year forecast: $30.00

Why we're watching:

• Analyst support: True, SPNT only has one analyst rating at present. However, it’s a bullish one: B. Riley Securities researcher Randy Binner (a top 13% rated analyst) recently initiated coverage with a Strong Buy rating and $30 price target, suggesting nearly 50% upside potential in the coming year. See the ratings
• Recent catalyst: SiriusPoint just acquired Assist America, expanding their IMG services division. This isn't just another small add-on – it's a strategic move that positions them for enhanced growth in a sector that's seeing increased demand.
• Industry ranking context: SPNT is currently the #1 highest-rated stock in the Reinsurance Insurance industry, which has an Industry Rating of A.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — SPNT's top industry position reflects its strong fundamentals and growth trajectory in the reinsurance sector.
• Component Grades: The company shows particular strength with an A grade in both Growth and Sentiment, while maintaining a B in Value and Artificial Intelligence capabilities, indicating well-rounded fundamentals across key investment metrics. (See all 7 Zen Component Grades here)

2- Ibex Ltd (NASDAQ: IBEX)

IBEX Limited operates a Customer Lifecycle Experience platform providing solutions spanning the entire customer lifecycle. It’s also our most recent Stock of the Week. The company recently reported record-breaking fiscal 2026 results and raised full-year guidance, demonstrating strong operational momentum in the information technology services sector. 

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $38.11 — get current quote

Max 1-year forecast: $40.00

Why we're watching:

• As our Editor-in-Chief Steve Reitmeister states, there are multiple reasons why IBEX aligns with his 2026 strategy: 
• First, Size Matters: This is a Small Cap software stock at only $513 million market cap. Market valuation metrics are very clear that large caps are overpriced while small caps have the most upside potential. 
• Second, it has a STRONG Zen Ratings profile. It is not just an A rated stock (which is the top 5% of all stocks analyzed). It is actually in the top 1% out of nearly 4,500 companies reviewed by the model. 
• Consistency: The company has beaten expectations consistently, with recent Q1 2026 earnings showing strong execution and record performance that led management to raise full-year guidance.
• Industry ranking context: IBEX is currently the #1 highest-rated stock in the Information Technology Service industry, which has an Industry Rating of C.
• Zen Rating highlights: In addition to its aforementioned A (Strong Buy) rating, IBEX has strong Component Grades: As for Value and Financials highlight the company's attractive valuation metrics, and a B for Sentiment indicates Smart Money is already taking note. See all 7 Zen Component Grades here

A note from our sponsors...

3- Eli Lilly & Co (NYSE: LLY)

Eli Lilly is breaking out as it moves to acquire Ventyx Biosciences and heads into what many are calling the year of obesity pills — where Lilly’s lead in the GLP-1 market is only getting wider.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $1,040.81 — get current quote

Max 1-year forecast: $1,500.00

Why we're watching:

• Analyst support: Right now, we follow 17 analysts covering the stock. It has 11 Strong Buy, 3 Buy, and 3 Hold ratings, demonstrating strong bullish consensus. See the ratings
• UBS researcher Michael Yee (a top 19% rated analyst) recently assumed coverage with Strong Buy and a $1,250.00 price target (+17.53% upside), stating that LLY's innovative pipeline and strategic positioning serve as robust catalysts for long-term value creation.
• Bank of America's Tim Anderson (top 18%) maintains Strong Buy at $1,268.00 (+19.22% upside), highlighting significant potential in LLY's diabetes treatment offerings as a major revenue driver, while Wells Fargo's Mohit Bansal (top 15%) maintains Strong Buy at $1,200.00.
• Industry ranking context: LLY is currently the 2nd highest-rated stock out of 19 in the General Drug Manufacturer industry, which has an Industry Rating of A. (Want to see what’s rated #1? We featured it in this newsletter.)
• Zen Rating highlights: LLY is an A-rated (Strong Buy) stock, meaning it’s in the top 5% of stocks we track based on a rigorous 115-factor analysis. Stocks with this rating have historically delivered market-beating returns. 
• Component Grades: LLY boasts very strong Component Grades: An exceptional A for Sentiment, and above-average Bs in nearly every other category, including Growth, Value, Sentiment, Momentum, and our proprietary AI factor. The only C is for Safety — worth noting, but also fairly normal within the industry. See all 7 Zen Component Grades here

4- Enhabit (NYSE: EHAB)

Enhabit Inc is emerging as a healthcare standout — ranking #3 in its industry and benefiting from powerful demand tailwinds in home health and hospice care.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $10.05 — get current quote

Max 1-year forecast: $12.00

Why we're watching:

• Analyst support: Admittedly, EHAB only has one rating right now among the analysts we track — but it’s a bullish Strong Buy, with a price target that suggests over 20% potential upside. See the ratings
• The company is currently experiencing increasing market demand for medical care facilities, with strategic initiatives expected to enhance profitability and operational efficiencies throughout 2026.
• Industry ranking context: EHAB is currently the 3rd highest-rated stock out of 42 in the Medical Care Facility industry, which has an Industry Rating of A.
• With its Zen Rating of A (Strong Buy), EHAB is in a class of stocks that have historically delivered 32.52% annual returns — a testament to its growth potential in the expanding home healthcare market.
• Component Grades: EHAB has an exceptional Growth (A) grade combined with strong Safety (B) and Financials (B) scores, which demonstrate the company's balanced risk-reward profile.  See all 7 Zen Component Grades here

5- Taboola.com Ltd (NASDAQ: TBLA)

This AI-based algorithmic engine platform powers content recommendations across the open web for publishers and advertisers in Israel, the U.S., and internationally. It recently partnered with DeeperDive, its Gen AI answer engine — a catalyst that could lead to sustained growth.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $4.17 — get current quote

Max 1-year forecast: $6.00

Why we're watching:

• Analyst support: The stock only has 2 ratings among the analysts that we track, but they’re both Strong Buys — a good start to this stock’s entry. See the ratings
• Let’s look at who’s behind the ratings. First, Rosenblatt researcher Barton Crockett (a top 13% rated analyst) recently initiated coverage with a Strong Buy rating and $6 price target, representing over 40% upside potential.
• B. Riley Securities' Zach Cummins (a top 12% rated analyst) maintains a Strong Buy rating with a $4.50 price target, following the company's strong Q2 performance.
• 2025 was a good year for TBLA: The company demonstrated strong execution with aggressive share buybacks of nearly 12% in the first half of the year and raised full-year guidance across key metrics, while seeing exciting early traction with Realize, its new performance advertising platform.
• Industry ranking context: TBLA is currently the 2nd highest-rated stock out of 51  in the Internet Content & Information industry, which has an Industry Rating of B.
• Zen Rating highlights: As an A (Strong Buy) rated stock, TBLA is in a class of stocks that have historically delivered 32.52% annual returns. This positions it as a compelling play in the AI-driven advertising space.
• Component Grades: The company shows solid fundamentals with B grades in Growth and Financials, complemented by an A in Sentiment, reflecting growing investor optimism about its AI-powered content recommendation platform and new product launches. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.